[-] Show simple item record

dc.contributor.authorHawthorne, M. Frederick
dc.contributor.corporatenameUniversity of Missouri (System)en
dc.contributor.meetingnameMissouri Life Sciences Summit (2010: University of Missouri--Kansas City)en
dc.date.issued2010-02eng
dc.descriptionTranslational Medicine and Nanoscience Panelen
dc.description.abstractThe International Institute of Nano and Molecular Medicine (I2NM2) of the University of Missouri-Columbia is embarking upon an in-depth study of cancer therapy using the boron neutron capture reaction, the only binary radiation therapy of its type. To accomplish this extensive study the I2NM2 will lead by devising delivery vehicles for boron-10 which are specific for cancer cells. This study could benefit from collaboration with a research group interested in assisting us in the very extensive evaluation of new boron species in bio-distribution at I2NM2 and therapeutic work at the MU nuclear reactor (MURR). This would, above all, involve maintaining the supply of tumor-bearing mice using a variety of tumor models, cellular biology as it relates to therapeutic results, and treatment of experimental therapeutic data. The ultimate purpose of this initial study would be identification of superior boron target species which could then be evaluated in larger animals and eventually in humans.en
dc.identifier.urihttp://hdl.handle.net/10355/5482
dc.relation.ispartofAbstracts (Missouri Regional Life Sciences Summit 2010)en
dc.relation.ispartofcommunityUniversity of Missouri System. Missouri Summits. Missouri Regional Life Sciences Summit 2010
dc.subjectcancer therapyen
dc.subjectboron neutron capture reactionen
dc.subjectcellular biologyen
dc.subject.lcshCancer -- Treatmenten
dc.subject.lcshBoron-neutron capture therapyen
dc.subject.lcshCytologyen
dc.titleThe Vision of the International Institute of Nano and Molecular Medicine (I2NM2)en
dc.typePresentationen


Files in this item

[PDF]
[PDF]

This item appears in the following Collection(s)

[-] Show simple item record